Subscribe
L-R: Rachel Elsby, Nathaniel Leachman, Alexis Simpson, Renee Fuller
24 October 2024NewsAmericasMarisa Woutersen

Big Pharma counsel embrace AI but data and legal risks loom

Counsel from Pfizer, Gilead, and Bristol Myers Squibb spoke on AI’s transformative power and risks, reports Marisa Woutersen at LSPN Fall North America.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
LSPN Fall: Gilead GC shares top drafting tips
17 October 2024   At LSPN Fall North America, in-house counsel offered guidance on how to nail the perfect patent application. Marisa Woutersen reports.
Americas
LSPN Fall: Why Big Pharma is facing 'a balancing act'
17 October 2024   As the pharma sector grapples with legal and regulatory upheaval, LSPN Fall North America explored the need for companies to reassess their patent strategies. Marisa Woutersen reports.
Americas
HR, lobbying and business strategy…all in a day’s work for today’s counsel
22 October 2024   In-house pharma and biotech lawyers are taking on broader roles, from handling regulatory issues to corporate strategy—and outside counsel can help, finds Marisa Woutersen.


Editor's picks

Americas
Trump’s return sparks calls for pro-patent agenda
5 December 2024

Editor's picks

Americas
Trump’s return sparks calls for pro-patent agenda
5 December 2024
Americas
Comparing life sciences IP in Brazil and the US
28 November 2024
Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024
Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024
Unified Patent Court
‘Every CMS filing is painful’: Notes from a Unified Patent Court dispute
26 September 2024

More on this story

Americas
LSPN Fall: Gilead GC shares top drafting tips
17 October 2024   At LSPN Fall North America, in-house counsel offered guidance on how to nail the perfect patent application. Marisa Woutersen reports.
Americas
LSPN Fall: Why Big Pharma is facing 'a balancing act'
17 October 2024   As the pharma sector grapples with legal and regulatory upheaval, LSPN Fall North America explored the need for companies to reassess their patent strategies. Marisa Woutersen reports.
Americas
HR, lobbying and business strategy…all in a day’s work for today’s counsel
22 October 2024   In-house pharma and biotech lawyers are taking on broader roles, from handling regulatory issues to corporate strategy—and outside counsel can help, finds Marisa Woutersen.

More on this story

Americas
LSPN Fall: Gilead GC shares top drafting tips
17 October 2024   At LSPN Fall North America, in-house counsel offered guidance on how to nail the perfect patent application. Marisa Woutersen reports.
Americas
LSPN Fall: Why Big Pharma is facing 'a balancing act'
17 October 2024   As the pharma sector grapples with legal and regulatory upheaval, LSPN Fall North America explored the need for companies to reassess their patent strategies. Marisa Woutersen reports.
Americas
HR, lobbying and business strategy…all in a day’s work for today’s counsel
22 October 2024   In-house pharma and biotech lawyers are taking on broader roles, from handling regulatory issues to corporate strategy—and outside counsel can help, finds Marisa Woutersen.

More features

Novartis shields eye-drop patent at European Patent Office
CREATES Act unfairly tips the scales to generics
LSPN launches its first-ever US awards to celebrate life sciences leaders
Pharma giants seek closure on COVID-19 vaccine rows
How Inhibrx defended a $450m damages suit
Foley & Lardner adds litigation and transaction expert in New York
UPC deals further blow to Dexcom in glucose monitor dispute with Abbott
‘A marathon and a sprint at the same time’: How we won $452m damages